Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
前收盤價
US$27.42
−US$0.54 · -1.93%
盤中時間採用ET。市場資料可能有所延遲。
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
日內區間
目前US$27.42
52週區間
目前US$27.42
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
10
估值過高
情緒
59
多空交錯
風險
34
中等風險
動能
70
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
日內區間
目前US$27.42
52週區間
目前US$27.42
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 150萬 USD | 702萬 USD | 688.3萬 USD | 235.7萬 USD | 465.1萬 USD |
| 銷貨成本 | — | 1.64億 USD | 1.18億 USD | 8225.8萬 USD | 5331.1萬 USD |
| 毛利 | 150萬 USD | −1.57億 USD | −1.11億 USD | −7990.1萬 USD | −4866萬 USD |
| 研究與開發 | 2.45億 USD | 1.64億 USD | 1.18億 USD | 8225.8萬 USD | 5681.1萬 USD |
| 銷售、一般及管理費用 | 4380萬 USD | 3854.8萬 USD | 3091.4萬 USD | 2719.5萬 USD | 2048.8萬 USD |
| 營業費用 | 2.89億 USD | 3854.8萬 USD | 4341.4萬 USD | 3533.3萬 USD | 2258.3萬 USD |
| 利息收入 | 2861萬 USD | 3721.5萬 USD | 1311.3萬 USD | 290.9萬 USD | 50.5萬 USD |
| 折舊和攤銷 | 338萬 USD | 317.7萬 USD | 300.8萬 USD | 289.6萬 USD | 306.8萬 USD |
| 營業利益 | −2.87億 USD | −1.95億 USD | −1.55億 USD | −1.15億 USD | −7124.3萬 USD |
| 淨利 | −2.59億 USD | −1.58億 USD | −1.41億 USD | −1.12億 USD | −7051.1萬 USD |
公司資料更新於 2026年11月22日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$66.80
上漲空間 143.62%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2019年2月11日 | 1:15 | — | — |
股票分割 | 2008年3月10日 | 1:12 | — | — |
已生效 2019年2月11日
1:15
已生效 2008年3月10日
1:12
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI5929.53萬0.00%6893億 USD0.03%US$340.02-3.52%
iShares Russell 2000 ETFIWM5744.24萬0.08%715.37億 USD0.19%US$256.61-2.88%
State Street SPDR S&P Biotech ETFXBI4594.51萬0.48%96.36億 USD0.35%US$140.18-2.73%
Vanguard Extended Market ETFVXF2696.44萬0.03%302億 USD0.05%US$211.44-3.21%
iShares Russell 2000 Growth ETFIWO1664.01萬0.13%127.32億 USD0.24%US$320.43-3.57%
Vanguard Russell 2000 ETFVTWO1383.28萬0.08%168億 USD0.06%US$103.76-2.76%
Dimensional - US Small Cap ETFDFAS1286.14萬0.04%312.35億 USD0.30%US$74.24-2.48%
Schwab U.S. Small-Cap ETFSCHA1143.31萬0.06%204.47億 USD0.03%US$30.51-2.83%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
State Street SPDR S&P Biotech ETFXBI
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Vanguard Russell 2000 ETFVTWO
Dimensional - US Small Cap ETFDFAS
Schwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。